Possibilities of multi-vector therapy with N-acetylcysteine in the treatment of acute bronchitis

Acute bronchitis (AB) is an acute inflammation of the bronchial tissue, which often occurs in association with upper respiratory tract infections in the absence of chronic bronchopulmonary diseases. Etiologic agent of AB is rarely determined, but in most cases, it is caused by viruses and much less often by bacteria. If the patient has chronic bronchopulmonary pathology (for example, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis), acute inflammation of the tracheobronchial tree is an exacerbation of the chronic disease, and not AB. It is fundamentally important to distinguish between these clinical situations due to the difference in approaches to their therapy and possible outcomes. In the treatment of OB, symptomatic therapy is used most often. In that case leading role is played by mucoactive drugs, although in some cases it may be necessary to prescribe other groups of medicines – antibiotics, inhaled glucocorticosteroids, antitussives. The aim of the article: to highlight the possibilities of multi-vector therapy of this disease by means of N-acetylcysteine use.